A four-kallikrein panel for the prediction of repeat prostate biopsy: Data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands

British Journal of Cancer

Volumn 103, Issue 5, 2010, Pages 708-714

  Gupta, A ^a   Roobol, M J ^b   Savage, C J ^a   Peltola, M ^c   Pettersson, K ^b   Scardino, P T ^a   Vickers, A J ^a   Schroder F H ^b   Lilja, H ^a,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TURKU   (Finland)

^d LUND UNIVERSITY   (Sweden)

Author keywords

biomarkers; cancer screening; predictive value of tests; prostate cancer; prostate specific antigen

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

BIOPSY; EARLY DETECTION OF CANCER; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NETHERLANDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77955981143     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605815     Document Type: Article

References (36)

1. Benecchi L, Pieri AM, Melissari M, Potenzoni M, Pastizzaro CD (2008) A novel nomogram to predict the probability of prostate cancer on repeat biopsy. J Urol 180(1): 146-149
2. Catalona WJ, Beiser JA, Smith DS (1997) Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol 158(6): 2162-2167
3. Chun FK, Briganti A, Graefen M, Porter C, Montorsi F, Haese A, Scattoni V, Borden L, Steuber T, Salonia A, Schlomm T, Latchemsetty K, Walz J, Kim J, Eichelberg C, Currlin E, Ahyai SA, Erbersdobler A, Valiquette L, Heinzer H, Rigatti P, Huland H, Karakiewicz PI (2007) Development and external validation of an extended repeat biopsy nomogram. J Urol 177(2): 510-515
4. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M (2000) Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 163(4): 1144-1148; discussion 1148-1149
5. Durkan GC, Greene DR (1999) Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? BJU Int 83(1): 34-38
6. Fleshner NE, OSullivan M, Fair WR (1997) Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 158(2): 505-508; discussion 508-509
7. Haese A, De la Taille A, Van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, Van Gils MP, Schalken JA (2008) Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54(5): 1081-1088
8. Keetch DW, Catalona WJ, Smith DS (1994) Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151(6): 1571-1574
9. Kranse R, Roobol M, Schroder FH (2008) A graphical device to represent the outcomes of a logistic regression analysis. Prostate 68(15): 1674-1680
10. Lane BR, Zippe CD, Abouassaly R, Schoenfield L, Magi-Galluzzi C, Jones JS (2008) Saturation technique does not decrease cancer detection during followup after initial prostate biopsy. J Urol 179(5): 1746-1750; discussion 1750
11. Letran JL, Meyer GE, Loberiza FR, Brawer MK (1998) The effect of prostate volume on the yield of needle biopsy. J Urol 160(5): 1718-1721
12. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW (2003) A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J Urol 170(4Pt 1): 1184-1188; discussion 1188
13. Lujan M, Paez A, Santonja C, Pascual T, Fernandez I, Berenguer A (2004) Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions. Prostate Cancer Prostatic Dis 7(3): 238-242
14. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J (2007) PCA3molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69(3): 532-535
15. O'Dowd GJ, Miller MC, Orozco R, Veltri RW (2000) Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 55(4): 553-559
16. Park SJ, Miyake H, Hara I, Eto H (2003) Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. Int J Urol 10(2): 68-71
17. Radwan MH, Yan Y, Luly JR, Figenshau RS, Brandes SB, Bhayani SB, Bullock AD, Liefu Y, Andriole GL, Kibel AS (2007) Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology 69(6): 1121-1127
18. Rietbergen JB, Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schroder FH (1998) Repeat screening for prostate cancer after 1-year followup in 984biopsied men: clinical and pathological features of detected cancer. J Urol 160(6Pt 1): 2121-2125
19. Rochester MA, Pashayan N, Matthews F, Doble A, McLoughlin J (2009) Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population. BMC Urol 9: 7
20. Roehrborn CG, Pickens GJ, Sanders JS (1996) Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology 47(3): 347-352
21. Roobol MJ, Kirkels WJ, Schroder FH (2003) Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 92(Suppl 2): 48-54
22. Roobol MJ, Schroder FH, Kranse R (2006) A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75years using a biopsy indication of 3.0ng/ml (results of ERSPC, Rotterdam). Prostate 66(6): 604-612
23. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, Van Der Kwast T, Blijenberg BG, Moss SM, De Koning HJ, Auvinen A (2009a) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13): 1320-1328
24. Schroder FH, Van den Bergh RC, Wolters T, Van Leeuwen PJ, Bangma CH, Van Der Kwast TH, Roobol MJ (2009b) Eleven-Year Outcome of Patients with Prostate Cancers Diagnosed During Screening After Initial Negative Sextant Biopsies. Eur Urol 57(2): 256-266
25. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW (2008) An updated catalog of prostate cancer predictive tools. Cancer 113(11): 3075-3099
26. Stewart CS, Leibovich BC, Weaver AL, Lieber MM (2001) Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 166(1): 86-91; discussion 91-92
27. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman Jr CA (2006) Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98(8): 529-534
28. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman Jr CA (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0ng/ml or lower. JAMA 294(1): 66-70
29. Ulmert D, Cronin AM, Bjork T, O Brien MF, Scardino PT, Eastham JA, Becker C, Berglund G, Vickers AJ, Lilja H (2008) Prostate-specific antigen at or before age 50as a predictor of advanced prostate cancer diagnosed up to 25years later: a case-control study. BMC Med 6: 6
30. Vaisanen V, Peltola MT, Lilja H, Nurmi M, Pettersson K (2006) Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab)2 fragments. Anal Chem 78(22): 7809-7815
31. Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H (2008) A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 6: 19
32. Vickers AJ, Cronin AM, Aus G, Pihl C, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H (2010a) Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer 116(11): 2612-2620
33. Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Schroder FH, Lilja H (2010b) A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Prostate Cancer Screening, Rotterdam. Clin Cancer Res 16(12): 3232-3239
34. Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Schroder FH, Lilja H (2010c) Reducing unnecessary biopsy during prostate cancer screening using a four kallikrein panel: an independent replication. J Clin Oncol 28(15): 2493-2498
35. Walz J, Graefen M, Chun FK, Erbersdobler A, Haese A, Steuber T, Schlomm T, Huland H, Karakiewicz PI (2006) High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 50(3): 498-505
36. Yanke BV, Gonen M, Scardino PT, Kattan MW (2005) Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol 173(2): 421-424